Ligand Pharmaceuticals Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−0.45%
vs ±7.5% implied · ×0.06
shaded = implied · ▲▼ = realized
Ligand Pharmaceuticals has 6 disclosed suppliers and 25 disclosed customers in SEC filings.
Ligand Pharmaceuticals Inc
319.37
SentenceIn repayment of the Investment Amount, we will remit 17.0% of revenues related to the Products until an annual total of $17.0 million has been remitted to Ligand, thereafter we will remit (a) 4.0% of revenues related to the Primary Product in the field of hypertension treatment and (b) 4.0% of revenues related to the Secondary Product in the field of coronary artery treatment.
basisOBIO FY2025 revenue $33MLGND FY2025 revenue $268M
SentenceIn May 2024, we, and certain wholly-owned subsidiaries, entered into a Purchase and Sale Agreement (the "Ligand Purchase Agreement") with Ligand Pharmaceuticals Incorporated ("Ligand") for the sale to Ligand of (i) 31.875% of the development, regulatory and commercial milestone payments we were then eligible to receive under our agreements with BMS, UroGen, Gilead, Merck and Incyte, (the "Covered License Agreements") (ii) 18.75% of the royalties we receive under the Covered License Agreements; and (iii) a 2.625% synthetic royalty on worldwide net sales of botensilimab and balstilimab (collectively the "Purchased Assets").
SentenceWe have otherwise primarily funded our business through the sale of our capital stock and through the entry into the royalty, license and termination agreement ("RLT Agreement") with Takeda Company Limited ("Takeda"), which resulted in a one-time up-front payment of $196.0 million in 2021 and the entry into a Royalty Monetization Agreement (the "Ligand Agreement") with Ligand Pharmaceuticals Incorporated ("Ligand"), which resulted in a one-time up-front payment of $30.0 million in 2023.
SentenceThe MSA between Ligand and the Company provides Ligand, Ligand affiliated parties or third-party licensees with an ability to source commercial or developmental supply of API, while also providing the Company with the associated economics of the supply of such material.
SentenceWe also have commitments under our supply agreement with Hovione for Captisol purchases.
LGND 10-Kaccession 0000886163-25-000012
SentenceUnder the Ligand Agreement, we received from Ligand an exclusive (even as to Ligand), sublicensable license, under relevant know-how and certain patents owned or in-licensed by Ligand, to develop, manufacture and sell Licensed Products for oral use in the Licensed Territory.
SentenceWe supply Captisol to, and receive royalties from, Acrotech Biopharma for sales of Evomela in the United States, and CASI Pharmaceuticals for sales in China.
LGND 10-Kaccession 0000886163-26-000006
SentenceOur commercialization partner, Alvogen, launched the product in June 2020 in the United States.
LGND 10-Kaccession 0000886163-26-000006
SentenceOn September 24, 2025, we invested $7 million in strategic capital to purchase economic rights from Arecor Limited ("Arecor"), with an additional $1 million in deferred consideration payable in two equal parts at the six- and twelve-month anniversaries of the transaction closing date.
LGND 10-Kaccession 0000886163-26-000006
SentenceWe have a license agreement with Baxter, related to Nexterone, a Captisol-enabled formulation of amiodarone, which is marketed in the United States and Canada.
LGND 10-Kaccession 0000886163-26-000006
SentenceWe supply Captisol to, and receive royalties from, Acrotech Biopharma for sales of Evomela in the United States, and CASI Pharmaceuticals for sales in China.
LGND 10-Kaccession 0000886163-26-000006
SentenceTravere has also partnered with Chugai Pharmaceuticals to develop and commercialize Filspari in Japan and other Asian countries.
LGND 10-Kaccession 0000886163-26-000006
SentenceIn February 2024, Travere and its partner CSL Vifor received approval for Filspari for the treatment of IgAN in Europe.
LGND 10-Kaccession 0000886163-26-000006
SentenceWe acquired economic rights to Qtorin™ 3.9% rapamycin anhydrous gel (Qtorin rapamycin, formerly PTX-022) from Palvella in December 2018.
LGND 10-Kaccession 0000886163-26-000006
SentenceAs of December 31, 2025, Recordati was the largest individual marketer and payor of our financial royalty assets, representing 54% of these assets.
LGND 10-Kaccession 0000886163-26-000006
SentenceSII began commercialization of its 10-valent pneumococcal conjugate vaccine, Pneumosil, which is produced using CRM197 made in the Pelican Expression Technology platform, in the second quarter of 2020.
LGND 10-Kaccession 0000886163-26-000006
SentenceContract revenue and other revenue increased by $9.5 million primarily due to milestone payments earned from Verona Pharma upon the approval and commercial launch of Ohtuvayre.
LGND 10-Kaccession 0000886163-25-000012
Expected move
No implied move.